Implications of HCV genotype 3 specific immunity on cross-reactive vaccine design by von Delft, A, Annette von Delft

An update on SARS-CoV-2 clinical trial results—what we can learn for the next pandemic by Arman, BY, Brun, J, Hill, ML, Zitzmann, N, von Delft, A

Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes by Donnison, T, von Delft, A, Brown, A, Swadling, L, Hutchings, C, Hanke, T, Chinnakannan, S, Barnes, E

A pan-genotype HCV T cell vaccine, in a simian adenovirus vector, to target T cell epitopes conserved across multiple HCV genotypes by Donnison, T, Von Delft, A, Chinnakannan, S, Lourenco, J, Hutchings, C, Brown, A, Klenerman, P, Barnes, E

Accelerating antiviral drug discovery: lessons from COVID-19 by von Delft, A, Hall, MD, Kwong, AD, Purcell, LA, Saikatendu, KS, Schmitz, U, Tallarico, JA, Lee, AA

The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes by von Delft, A, Donnison, T, Lourenço, J, Hutchings, C, Mullarkey, C, Brown, A, Pybus, O, Klenerman, P, Chinnakannan, S, Barnes, E

Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Sarac... by Smilde, BJ, Stockklausner, C, Keen, R, Whittaker, A, Bullock, AN, von Delft, A, van Schoor, NM, Yu, PB, Eekhoff, EMW

Immune responses in acute and chronic HCV genotype 3a infection detected by two distinct techniques by von Delft, A, Humphreys, I, Pfafferot, K, Lucas, M, Swadling, L, Brown, A, Lauer, G, Gaudieri, S, Klenerman, P, Barnes, E

The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design. by von Delft, A, Humphreys, I, Brown, A, Pfafferott, K, Lucas, M, Klenerman, P, Lauer, G, Cox, A, Gaudieri, S, Barnes, E

HCV genotype-3a T cell immunity: specificity, function and impact of therapy by Humphreys, IS, von Delft, A, Brown, A, Hibbert, L, Collier, J, Foster, G, Rahman, M, Christian, A, Klenerman, P, Barnes, E

HCV genotype-3a T cell immunity: Specificity, function and impact of therapy by Humphreys, I, Von Delft, A, Brown, A, Hibbert, L, Collier, J, Foster, G, Rahman, M, Christian, A, Klenerman, P, Barnes, E

HCV genotype-3a T cell immunity: specificity, function and impact of therapy. by Humphreys, I, von Delft, A, Brown, A, Hibbert, L, Collier, J, Foster, G, Rahman, M, Christian, A, Klenerman, P, Barnes, E

'Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological r... by Bucci, C, von Delft, A, Christian, A, Flemming, V, Harrison, A, Halliday, J, Collier, J, Manganis, C, Klenerman, P, Irving, W, Barnes, E

Emergence of a distinct HIV-specific IL-10-producing CD8+ T-cell subset with immunomodulatory functions during chronic HIV-1 infection. by Clutton, G, Yang, H, Hancock, G, Sande, N, Holloway, C, Angus, B, von Delft, A, Barnes, E, Borrow, P, Pellegrino, P, Williams, I, McMichael, A, Dorrell, L

Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses by Yang, H, Llano, A, Cedeño, S, von Delft, A, Corcuera, A, Gillespie, GM, Knox, A, Leneghan, DB, Frater, J, Stöhr, W, Fidler, S, Mothe, B, Mak, J, Brander, C, Ternette, N, Dorrell, L

Highly immunogenic virally vectored T-cell vaccines cannot overcome subversion of the T-cell response by HCV during chronic infection by Swadling, L, Halliday, J, Kelly, C, Brown, A, Capone, S, Ansari, M, Bonsall, D, Richardson, R, Hartnell, F, Collier, J, Ammendola, V, Del Sorbo, M, Von Delft, A, Traboni, C, Hill, A, Colloca, S, Nicosia, A, Cortese, R, Klenerman, P, Folgori, A, Barnes, E

Highly-immunogenic virally-vectored T-cell vaccines cannot overcome subversion of the T-cell response by HCV during chronic infection by Swadling, L, Halliday, J, Kelly, C, Brown, A, Capone, S, Ansari, M, Bonsall, D, Richardson, R, Hartnell, F, Collier, J, Ammendola, V, Del Sorbo, M, Von Delft, A, Traboni, C, Hill, A, Colloca, S, Nicosia, A, Cortese, R, Klenerman, P, Folgori, A, Barnes, E

Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans by Kelly, C, Swadling, L, Capone, S, Brown, A, Richardson, R, Halliday, J, von Delft, A, Oo, Y, Mutimer, D, Kurioka, A, Hartnell, F, Collier, J, Ammendola, V, Sorbo, M, Grazioli, F, Esposito, M, Marco, S, Siani, L, Traboni, C, Hill, A, Colloca, S, Nicosia, A, Cortese, R, Folgori, A, Klenerman, P, Barnes, E

Chronic Hepatitis C Virus infection subverts vaccine induced T-cell immunity in humans. by Kelly, C, Swadling, L, Capone, S, Brown, A, Richardson, R, Halliday, J, von Delft, A, Oo, Y, Mutimer, D, Kurioka, A, Hartnell, F, Collier, J, Ammendola, V, Del Sorbo, M, Grazioli, F, Luisa Esposito, M, Di Marco, S, Siani, L, Traboni, C, Hill, A, Colloca, S, Nicosia, A, Cortese, R, Folgori, A, Klenerman, P, Barnes, E

Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus by Ansari, M, Pedergnana, V, Ip, C, Magri, A, Von Delft, A, Bonsall, D, Chaturvedi, N, Bartha, I, Smith, D, Nicholson, G, McVean, G, Trebes, A, Piazza, P, Fellay, J, Cooke, G, Foster, G, STOP-HCV Consortium, Hudson, E, McLauchlan, J, Simmonds, P, Bowden, R, Klenerman, P, Barnes, E, Spencer, C